Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5 DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene ther ...